Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma by unknown
Genomic analyses reveal FAM84B and the NOTCH
pathway are associated with the progression of
esophageal squamous cell carcinoma
Cheng et al.
Cheng et al. GigaScience  (2016) 5:1 
DOI 10.1186/s13742-015-0107-0
RESEARCH Open Access
Genomic analyses reveal FAM84B and the
NOTCH pathway are associated with the
progression of esophageal squamous cell
carcinoma
Caixia Cheng1,2,3†, Heyang Cui1,2†, Ling Zhang1,2†, Zhiwu Jia1,2†, Bin Song1,2,4†, Fang Wang1,2†, Yaoping Li1,5,
Jing Liu1,6, Pengzhou Kong1,2, Ruyi Shi1,2, Yanghui Bi1,2, Bin Yang1,2,5, Juan Wang1,2, Zhenxiang Zhao1,2,
Yanyan Zhang1,6, Xiaoling Hu1,2, Jie Yang1,2, Chanting He1,2, Zhiping Zhao1,2, Jinfen Wang7, Yanfeng Xi7, Enwei Xu7,
Guodong Li7, Shiping Guo5, Yunqing Chen5, Xiaofeng Yang8, Xing Chen9, Jianfang Liang3, Jiansheng Guo6,
Xiaolong Cheng1,2, Chuangui Wang10, Qimin Zhan11* and Yongping Cui1,2*
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal cancer worldwide and the fourth
most lethal cancer in China. Genomic characterization of tumors, particularly those of different stages, is likely to
reveal additional oncogenic mechanisms. Although copy number alterations and somatic point mutations
associated with the development of ESCC have been identified by array-based technologies and genome-wide
studies, the genomic characterization of ESCCs from different stages of the disease has not been explored. Here, we
have performed either whole-genome sequencing or whole-exome sequencing on 51 stage I and 53 stage III ESCC
patients to characterize the genomic alterations that occur during the various clinical stages of ESCC, and further
validated these changes in 36 atypical hyperplasia samples.
Results: Recurrent somatic amplifications at 8q were found to be enriched in stage I tumors and the deletions of
4p-q and 5q were particularly identified in stage III tumors. In particular, the FAM84B gene was amplified and
overexpressed in preclinical and ESCC tumors. Knockdown of FAM84B in ESCC cell lines significantly reduced in vitro
cell growth, migration and invasion. Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their
pathways showed no significant difference between stage I and stage III tumors, we identified and validated a
prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the
preclinical and early stages of ESCC.
Conclusions: Our results suggest that FAM84B and the NOTCH pathway are involved in the progression of ESCC
and may be potential diagnostic targets for ESCC susceptibility.
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Background
Esophageal squamous cell carcinoma (ESCC) is the
eighth most common and the sixth most lethal cancer
worldwide with approximately 70 % of global esophageal
cancer occurring in China [1]. ESCC is more prevalent
in non-Caucasian populations, with the highest inci-
dence in the Taihang Mountain region of North-Central
China [1], and known risk factors include environmental
factors such as dietary habits (e.g. the consumption of
hot food and betelnut chewing), family history, alcohol
abuse and tobacco smoking [2–4]. ESCC has a highly
variable clinical outcome, with an excellent prognosis for
stage I and II tumors but a poor outcome for later stage
tumors [1]. Currently, three types of treatment are avail-
able: surgery, chemotherapy and radiation therapy [5].
Among these, chemoradiotherapy (CRT) is recognized
as one of the most effective treatments for ESCC [6].
However, as with other treatments, the clinical response
to CRT varies between individuals, and this has a major
influence on clinical care outcomes [7, 8]. The 5-year
survival rate ranges from 10 % to 25 %, and is highly
dependent on tumor stage [9].
The genomic characterization of ESCC tumors, par-
ticularly those from different stages of the disease, is
likely to reveal underlying oncogenic mechanisms and
new cancer-associated genes [10]. ESCC initiates from
atypical hyperplasia and progresses to carcinoma in situ
and then invasive carcinoma [11]. Biomarkers identified
from atypical hyperplasia or from early-stage tumors
may lead to the development of new diagnostic, prog-
nostic, therapeutic and prevention strategies. Analyses of
somatic copy number alterations (SCNAs) using array-
based technologies have identified frequently altered re-
gions such as 3q26 [12], 11q13.3 [13] and 8q24.3 [14],
and exome-wide investigations have revealed point mu-
tations in the well-known cancer-associated genes TP53,
PIK3CA, CDKN2A and novel genes ZNF750, FAT1,
FAT2 and FAM135B [15–17]. However, the genetic or
mechanistic alterations related to the progression of
ESCC have not been fully elucidated. Thus, there is an
urgent need to elucidate the genomic alterations and
molecular events associated with the various ESCC
stages to enhance our understanding of these tumors,
aid in early diagnosis, identify therapeutic targets and
develop prevention strategies.
In this study, we used whole-genome sequencing
(WGS) of 14, whole-exome sequencing (WES) of 90 and
deep target capture sequencing (TCS) of 96 ESCC tu-
mors and adjacent normal tissue from patients recruited
from the Taihang Mountain region in North-Central
China. This cohort includes 51 stage I and 53 stage III
cases from the Han Chinese population who live in the
Shanxi and Henan provinces. The genetic alterations
that we identified were further validated through next-
generation sequencing (NGS) and their association with
a specific clinical stage was confirmed by comparison
with 36 atypical hyperplasia (i.e. premalignant) tissues.
Data description
Genomic DNAs were extracted from 3 stage IA, 48 stage
IB, 31 stage IIIA, 17 stage IIIB, 5 stage IIIC tumors and
matched normal tissues (Additional file 1: Table S1)
[18]. WGS libraries (500 bp inserts) and WES libraries
(150–200 bp inserts) were constructed and sequenced
on an Illumina HiSeq 2000 sequencer using 90 bp
paired-end reads. TCS was performed following a proto-
col similar to WES (see Methods). Sequencing reads
from the Illumina HiSeq 2000 sequencer were processed
by Illumina software and passed to the in-house pipeline
to determine somatic point mutations, indels, and copy
number variations. A significance analysis method, Mut-
SigCV, was used to identify significantly mutated genes
(SMGs). Fluorescence in situ hybridization (FISH), qPCR
copy number analyses or targeted PCR-Sanger sequen-
cing was used to validate stage-associated genetic alter-
ations in 36 atypical hyperplasia tissues. To introduce
the gene that encodes the family with sequence similar-
ity 84, member B protein (FAM84B; also known as
NSE2) or scrambled control siRNAs into ESCC cells, we
used the pLKO.1 virus according to the manufacturer’s
instructions. Western blotting was carried out using
standard protocols [19] and tissue microarray resourced
immunohistochemistry analysis and functional assays
were performed as specified in the Methods section.
Results
The genome landscape of ESCC and its stage-associated
variations
We performed genome sequencing on DNA from 104
ESCC tumors and matched adjacent normal tissues, in-
cluding 51 stage I and 53 stage III cases (Additional file
1: Table S1) [18]. Five stage I and nine stage III tumors
underwent WGS (median coverage of 65×); 46 stage I
and 44 stage III tumors underwent WES (median cover-
age of 132×; Additional file 2: Figure S1). The average
number was 3.9 coding mutations/Mb for WGS and 2.4
non-silent mutations/Mb for WES (Additional file 3:
Table S2) [18]. Candidate non-silent mutations identified
from 48 stage I and 48 stage III tumors were selected for
TCS (at least 365×; Additional file 3: Table S2C) [18].
The validation rates were 97.8 % for identified single-
nucleotide variations (SNVs) and 58 % for indels. Conse-
quently, we obtained 10,330 somatic point mutations in
total: of these, 65 % resulted in missense changes and 6
% resulted in nonsense changes. There were 184 alter-
ations of splice sites and 90 small indels: of the indels,
84 % introduced frameshifts and 16 % were in-frame
(Additional file 4: Table S3 and Additional file 5: Figure
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S2B). We found 73 (range 24–189) non-silent mutations
per tumor in this cohort, and this rate is in line with
published rates (Additional file 5: Figure S2C) [15–17,
20], underscoring the representative nature of our
analysis.
Next, to identify possible differences in the overall
genomic architecture between stage I and stage III tu-
mors, we compared the spectrum of mutations and
broad SCNAs in these two sets. We observed no clear
difference between stage I and stage III tumors in terms
of genome-wide somatic SNV counts, even when the
groups were subdivided into stage IA, IB, IIIA, IIIB and
IIIC (Additional file 6: Figure S3). However, we observed
marked differences in the stage-associated pattern of
SCNAs. Stage I tumors harbored fewer SCNAs than
stage III tumors (p < 2.2 × 10−16, Fig. 1a) but there was
no correlation within sub-stage IIIA, IIIB or IIIC
(Additional file 6: Figure S3B). Genomic identification of
significant targets in cancer (GISTIC) [21] analysis in
the WGS set yielded universal deletions affecting 4p,
11p, 16p, 19p and 19q, and frequent gains of 3q, 5p, 7p,
7q, 8p, 8q, 12p, 14q, 18p, 20q, 21q, Xp and Xq
(Additional file 6: Figure S3C). In particular, recurrent
somatic amplifications at 8q (containing MYC and
FAM84B) [22] were found to be enriched in stage I tu-
mors; the deletions of 4p-q (containing VEGFC, FBXW7
and FAT1) [23, 24] and 5q (containing PTTG and
MAML1) [25, 26] were particularly identified in stage III
tumors (p < 0.05, Fisher’s exact test, Fig. 1b), suggesting
that these alterations are associated with stage progres-
sion. Furthermore, copy-number analyses verified the
amplifications of candidate genes located within these
significantly altered regions in 36 atypical hyperplasia
tissues (Fig. 1c). Thus, although stage I and stage III tu-
mors of ESCC are genomically similar, our results reveal
that the copy-number variations exhibit a pattern that is
associated with the clinical stage of the tumor.
We also applied a modified GISTIC method to profile
genome segments with copy number variations in the 14
tumors analyzed by WGS, which revealed 126 signifi-
cantly altered regions (Additional file 7: Figure S4).
Moreover, to identify genes affected by recurrent
Fig. 1 Comparison of copy-number alterations between stage I and stage III ESCC tumors. a Comparison of broad structural genome alterations
between stage I and stage III ESCC tumors. Analysis is based on absolute copy numbers. Whole-genome sequencing-based analyses reveal that
stage III harbor markedly more SCNAs than stage I tumors (p < 2.2 × 10−16). b Significant, focally amplified (red, left panel) and deleted (blue, right
panel) regions of stage I (upper) and stage III (lower) are plotted along the genome. The line represents a G-score of 0.1. The black arrows show
significantly amplified regions in stage I tumors or deleted regions in stage III tumors. c Left panel: Copy number assay by qPCR of candidate
genes located in regions significantly associated with various tumor stages in 36 atypical hyperplasia tissues (blue). The RNase P gene was used
as reference normal (red). Data are mean ± SD. All assays were performed in triplicate. Right panel: The percentage of cases with copy-number
amplification for MYC, FAM84B or copy-number loss for FBXW7, FAT1 and PTTG in 36 atypical hyperplasia tissues
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SCNAs, we manually inspected the 126 significantly al-
tered regions using the Integrative Genomics Viewer
(IGV). This approach identified recurrent focal CNAs,
including one of the most amplified regions, 8q24.13-
q24.21, which contains FAM84B (Additional file 8: Table
S4) [27]. Amplification of this gene was found in 44 %
(46 out of 104) of patients (Fig. 2a and Additional file 9:
Figure S5) and this was further validated by fluorescence
in situ hybridization (FISH) in atypical hyperplasia tis-
sues and ESCC tumors (Fig. 2b). FAM84B is involved in
the formation of DNA-repair complexes and little is
known about its function in human cancers [27]. In our
cohort of 104 patients, this gene was markedly highly
expressed in 57 % of cases (the immunoreactivity score
for FAM84B expression in tumors was at least double
that of matched normal tissue, TIRS/NIRS > 2, Fig. 2c).
To verify the specific abundance of this gene during the
initiation of ESCC, we used immunohistochemistry on
tissue microarray-sourced preclinical and ESCC samples.
We observed a marked relative increase in FAM84B ex-
pression in atypical hyperplasia samples compared with
that of normal tissues (Fig. 2d). In addition, we knocked
down FAM84B in KYSE150 and TE-1 cells that have
high levels of endogenous FAM84B and observed that
FAM84B depletion attenuated cell growth, migration
and invasion (Fig. 3). This finding suggests that FAM84B
amplification and the resultant increased levels of
FAM84B protein are associated with progression from
normal squamous epithelium to ESCC and may be a po-
tential diagnostic marker for susceptibility to ESCC.
Significantly mutated genes
For most cancer types, genomic landscapes consist of
many ‘hills’ (corresponding to genes that are altered in a
low percentage of the tumors) and a small number of
‘mountains’ (genes that are altered in a higher percent-
age of tumors) [28]. This also holds true for ESCC, as re-
vealed by our cohort (Additional file 10: Figure S6;
Additional file 11: Table S5) [18]. Only 14 genes (TP53,
TTN, MUC16, NOTCH1, FAT1, PIK3CA, CSMD3,
PCLO, LRPIB, MLL2, EP300, SYNE1, SPTA1 and
PKHD1L1) contained somatic mutations that were de-
tected in at least 10 % of the samples whereas 85 genes
were mutated in 5-10 % of the tumors. The remaining
1,309 genes were altered in 2–5 % of the cohort of 104.
We applied MutSigCV to identify significantly mu-
tated genes (SMGs) associated with ESCC. This analysis
led to the identification of eight SMGs with q < 0.2
(Additional file 12: Table S6A). In general, the number
of SMGs in an individual cancer ranges from zero to
four. Of the 104 tumors that we comprehensively char-
acterized, 50 % (52 out of 104 cases) displayed mutations
in two or more SMGs, 44 % (46 out of 104 cases) of
cases harbored alterations in one SMG, and six cases did
not have mutations in any of the SMGs. We observed 21
different combinations of SMGs and so there seems to
be substantial variation in the drivers of oncogenesis.
Four of the eight SMGs (TP53, NOTCH1, PIK3CA and
FAT1) were mutated in more than 10 % of cases. Col-
lectively, these contributed 86 % (158 of 184) of the
non-silent mutations. The other four SMGs, each con-
tributing relatively infrequently, were responsible for the
remaining 14 % (26 of 184) of the non-silent mutations
(Fig. 4).
Identical mutations suggest stage-associated NOTCH
pathway alterations
To discern the SMGs and pathways relevant to tumori-
genic capacity and tumor progression in more detail, we
investigated the relationship between the prevalence of
each SMG and tumor stage and conducted separate
pathway analyses for stage I versus stage III tumors.
Interestingly, a pronounced diversity of NOTCH1 muta-
tions was observed in 35 % of stage I tumors but in only
8 % of stage III tumors (p < 0.0006, Fisher’s test). Like-
wise, NOTCH signaling, a fundamental signaling system
comprising the NOTCH receptor (including NOTCH1,
NOTCH2, NOTCH3 and NOTCH4), Delta and Serrate/
Jagged (DSL) ligands and CSL DNA-binding proteins
[28], was altered in 55 % of stage I tumors versus 32 %
of stage III tumors (p < 0.02, Fisher’s test, Fig. 5a). This
indicates that alteration of the NOTCH pathway may be
early event in the development of a subgroup of ESCCs.
NOTCH1 mutations are relatively common in head and
neck squamous cell carcinoma (HNSCC), lung SCC and
breast cancer, with 5 % to 15 % of tumors harboring
protein-coding changes [28–30]. In our cohort, 22 som-
atic mutations were identified in NOTCH1 with a muta-
tion frequency of 21 % (Additional file 12: Table S6B).
Of the 22 non-silent mutations, eight are nonsense, ten
are missense, three are frameshift indels and one is a
splicing site mutation, and these are, in general, all pre-
dicted to be loss-of-function mutations (Fig. 5b). Not-
ably, we found another six non-silent mutations
including four missense and two frameshift indels, with
a mutation frequency of 16.7 % in the 36 atypical hyper-
plasia tissues (Additional file 13: Table S7). Many of
these missense mutations occurred at or near important
domains such as the ligand-binding domain (EGF re-
peats). Moreover, the nonsense mutations observed in
NOTCH1 generate a premature stop codon, resulting in
a C-terminally truncated NOTCH1 protein lacking a
PEST sequence (a sequence rich in proline, glutamic
acid, serine and threonine) that is important for tran-
scription activation. In addition, five out of nine muta-
tions identified in NOTCH2/3 were truncating, and two
stopgains were identified in RBPJ, one of the target
genes of NOTCH. Thus, in contrast to T-cell acute
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Fig. 2 FAM84B is amplified and overexpressed in ESCC tumors. a Focally amplified (red) region containing FAM84B of the WGS set viewed by IGV
is plotted along the chromosome. b Representative immunofluorescence images show signals produced from FISH analyses using probes specific
to chromosome 2 (red) and FAM84B (green) in normal, preclinical atypical hyperplasia tissue and an ESCC sample. Scale bars, 5 μm. The bar graph
(right panel) shows the percentage of indicated cases with more than two FAM84B signals in each group. c FAM84B is highly expressed in ESCC
tumors. Representative immunohistochemistry images show FAM84B expression in ESCC tumors and matched normal tissues. The right image
shows FAM84B expression in one slide with tumor cells and adjacent normal cells. The bar graph (right panel) shows the percentage of indicated
cases with varying FAM84B expression levels in the 104 patient cohort. FAM84B expression level was based on subjective assessment of
immunohistochemical staining intensity (see Online Methods). Scale bars, 400 μm. ***p < 0.001. d Left panel: Representative images displaying
cytoplasmic positivity of FAM84B in normal esophagus tissue, atypical hyperplasia tissue, ESCC in situ and invasive ESCC tissues from large-scale
tissue microarraays (OD-CT-DgEso01-001, Shanghai Outdo Biotech Detail information of cases was shown in Additional file 16: Table S9). Right panel:
Cytoplasm expression significantly increases in atypical hyperplasia tissues, ESCC in situ and invasive ESCC tissues compared with that of normal
esophagus tissues based on a judgment of immunohistochemistry staining intensity (χ2-test). The normal esophagus tissues include 10 from the
OD-CT-DgEso01-001 array and 104 matched normal esophagus tissues from our sequenced cohort
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lymphoblastic leukemia, chronic lymphoblastic leukemia
and breast cancer, in which NOTCH1 serves as an onco-
gene [31], this pattern of mutations suggest that the
NOTCH pathway has a tumor suppressing role in ESCC.
Of related interest, 8 % of ESCC tumors (12 % of stage
I tumors and 4 % of stage III tumors) harbored muta-
tions in the F-box protein FBXW7 (Fig. 5a). FBXW7 is
the substrate-recognition subunit of an SCF-type ubiqui-
tin ligase complex that regulates the cell cycle by
targeting many proto-oncoproteins and antiapoptotic
molecules including NOTCH1, cyclin E, c-Myc, c-Jun
and mTOR for ubiquitin-mediated degradation. It there-
fore acts as a tumor suppressor protein [32] and has
been found to be mutated in various tumors [33, 34]. Of
the eight mutations detected in our cohort, two non-
sense and one frameshift deletion are inactivating muta-
tions (Fig. 5b, bottom panel). Moreover, most of the
mutations occur within the WD40 domain involved in
substrate recognition; mutation of this site prevents the
recognition of targets such as NOTCH1 for degradation.
Taken together, we identified 31 mutations in NOTCH
family genes. Most of these mutations result in trun-
cated protein products or have deleterious effects, sug-
gesting that NOTCH signaling is significantly disrupted
in our sample set and may be one of the main
mechanisms associated with the development of a sub-
group of ESCCs.
In addition to the NOTCH pathway, we found that
mutations in genes involved in several major metabolic
pathways were significantly enriched in the stage I
group. In particular, mutations occurred in genes associ-
ated with pyrimidine metabolism (31 % of stage I tumors
versus 13 % of stage III), glycine/serine/threonine metab-
olism (16 % versus 2 %) and fructose and mannose me-
tabolism (16 % versus 2 %). Conversely, the hedgehog
(Hh) signaling pathway showed a significantly higher
mutation frequency in the late stage III group (p < 0.05,
Fisher’s test; Additional file 14: Table S8). Thus, despite
there being no marked differences between the tumors
at various stages at the level of individual genes, such
differences seem to exist at the level of pathways. For
other frequently or significantly mutated genes, we
found no significant correlation between their mutation
frequencies and tumor stage.
Discussion
Clinical screening and surveillance approaches (i.e.
upper gastrointestinal endoscopy, barium esophagram,
non-endoscopy-based balloon cytology and serology
tumor markers etc.) for the early diagnosis of ESCC are
Fig. 3 FAM84B knockdown dramatically inhibited cell proliferation, cell migration and invasion. a The knockdown efficiency of FAM84B was
verified by western blotting analysis. Actin was used as a loading control. b MTT growth assay shows an increase in proliferation following
knockdown of FAM84B in KYSE150 and TE-1 cells. Data represent the mean ± SD; At least three independent experiments were performed; each
experiment was performed in triplicate. Statistical analysis was done using a two-sided t-test. *p < 0.05, **p < 0.01. c,d In vitro migration/invasion
assay with three experimental replicates revealed that knockdown of FAM84B significantly promotes cell migration and invasion in KYSE150 and
TE-1 cells. SCR indicates non-specific control siRNA. Each experiment was performed in triplicate; data are mean ± SD. *p < 0.05; **p < 0.01
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currently limited [1]. Hence, biomarkers indicating
ESCC pathogenic processes are urgently required to
diagnose and facilitate early intervention. Initial genomic
reports have described whole-genome and -exome
sequencing for ESCC patients [15–17]. Although in-
formative, these studies did not reveal the genomic dif-
ferences between tumors from various clinical stages.
In this study, we report the genomic characterization
of different stages of ESCC based on either WGS or
WES of 104 ESCC patients. We show that amplifications
of 8q and deletions of 4p-q and 5q may be associated
with the early stages of ESCC. Moreover, we identify
FAM84B as a novel ESCC-associated gene. Further func-
tional and clinical analyses strongly indicate that
FAM84B (located at 8q24.13-q24.21), which is highly
expressed in dysplasia and ESCC patients but not nor-
mal esophagus tissues, may contribute to oncogenesis in
ESCC and that targeting FAM84B may be a promising
strategy for the diagnosis of susceptibility and the early
stages of ESCC.
Similar to many other cancers, particularly esophageal
adenocarcinoma (EAC) [20], the well-defined cancer-
associated genes such as TP53, PIK3CA and CDKN2A
were also identified as SMGs in ESCC, providing evi-
dence of a common dysfunction in cell-cycle control
and apoptotic signaling. Importantly, the analysis of
ESCC genomes reveals that mechanisms previously sus-
pected to have a role in the biology of ESCC [15–17, 35]
but not in EAC [19] (for example, NOTCH1 and FBXW7)
are indeed involved in ESCC development (Additional file
15: Figure S7). Moreover, genomic characterization of dif-
ferent stages of ESCC tumors led us to identify dysregu-
lated NOTCH1 and NOTCH signaling predominantly in
stage I tumors, indicating the involvement of this gene
and its pathway in the early development of ESCC. Thus,
the prevalence of NOTCH1 provides a potential bio-
marker to detect ESCC in its early stages. NOTCH signal-
ing has long been known to function in developmental
processes and in regulating the self-renewal of tissues [36,
37]. Whereas activating mutations in NOTCH1 have been
identified in T-cell acute lymphoblastic leukemia and
breast cancer [38–40], a tumor suppressor role for
NOTCH signaling has been suggested in tumor types such
as chronic myelomonocytic leukemia (CMML) [41],
Fig. 4 A view of the genome landscape of ESCCs at various stages. a Stage-distributions of candidate driver mutations identified by MutSigCV
significance analysis. The type of each mutation is shown for every sample, including the gene-specific total number of mutated samples (right);
mutation subtypes are denoted by color. If multiple mutations were found in a gene in a single sample, only one is shown. The significance of
the mutations in each gene is shown to the left by the false discovery rate (FDR) q value. The lower bars indicate smoking/drinking status and
family history, respectively. The full list of mutated genes is given in Additional file 8: Table S4. b Percentage of ESCC patients harboring one or
two SMGs in the 104 cohort. The ESCC patients harboring none of the identified SMGs are also shown
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HNSCC [29] and lung SCC [42]. The spectrum of muta-
tions involving the NOTCH pathway in our cohort is con-
sistent with it having a tumor suppressor role in ESCC
rather than an oncogenic function. It is important to note
that although NOTCH1 has been reported to be a poor
survival marker in human ESCC [43], the correlation be-
tween genotype and the expression level of NOTCH1 re-
mains ambiguous.
Conclusion
In summary, we used the genomics data described
above, together with a large-scale tissue platform, to pin-
point molecular features linked to the early occurrence
of ESCC. We provide genetic and functional evidence
suggesting that overexpression of FAM84B is related to
the progression of ESCC and may be a potential diag-
nostic and/or therapeutic target. We also identify the
genomic aberrations that frequently alter the NOTCH
pathway in stage I ESCC tumors and which may be use-
ful for predicting early ESCC onset. Collectively, our re-
sults highlight the substantial stage-associated genetic
diversity underlying ESCC and facilitate the understand-
ing of the molecular defects that lead to early disease
onset, which may ultimately provide a set of potential
targets for its early diagnosis and prevention.
Methods
Samples and clinical data
We recruited tumor samples and adjacent normal tis-
sues from 104 ESCC patients from the Han Chinese
population who live in the Shanxi and Henan provinces,
Taihang Mountain, North-Central China. All samples
were obtained before treatment according to the guide-
lines of the local ethical committees (IRB of Shanxi
Medical University, Approval No. 2009029, and the Eth-
ics Committee of Henan Cancer Hospital, Approval No.
2009xjs12). This study was approved by the ethical com-
mittee of the Shanxi and Henan, China. All ESCC cases
collected for this study were staged using the American
Joint Committee on Cancer (AJCC) Cancer Staging
Standards, 7th Edition (2010). This cohort includes 51
cases of stage I tumors and 53 cases of stage III tumors.
Different subsets of patients were assayed on each plat-
form: 14 tumors and matched normal samples from 14
patients, including 5 cases of stage I and 9 cases of stage
III, had WGS data available (65×); 90 samples from 46
cases of stage I and 44 cases of stage III, had WES data
available (132×); 96 of the 104 samples including 48
cases of stage I and 48 cases of stage III had TCS data
available (365×) [18]. A detailed description of the clin-
ical characteristics of this cohort is shown in Additional
file 1: Table S1. A summary of the next-generation
Fig. 5 Identification of SMGs and pathways associated with early development of ESCC. a Comparison of stage I and stage III tumors. The
identified SMGs and top-ranked pathway predominant in stage I of ESCC are shown. Differences in SMGs and altered pathways between stage I
and stage III samples were statistically tested by Fisher’s exact test. b Schematic representation of the domain structure of the NOTCH family and
FBXW7, and the location of somatic mutations identified in ESCC tumors. The types and relative positions of confirmed somatic mutations are
shown in the transcripts of identified genes using the following symbols: stars, nonsense mutations; circles, missense mutations; diamond, mutations
at splice sites; triangles, small insertion or deletion. The upper symbols represent mutations identified in stage I and the lower ones represent mutations
identified in stage III tumors. c The main mutations involved in the NOTCH signaling pathway in this cohort. The overall percentage of patients carrying
these specific mutations is given and this is also broken down into stage I and stage III tumors
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sequencing analyses in this study is presented in
Additional file 2: Figure S1.
Sequencing
For WGS, genomic DNA extracted from 5 stage I tu-
mors, 9 stage III tumors and matched normal tissues
were randomly fragmented and purified. The WGS li-
braries were constructed and subjected to WGS on an
Illumina HiSeq 2000. At least 65× target depth and 30-
fold haploid coverage for tumors and normal samples
were achieved in all samples. A detailed description is
presented in Additional file 3: Table S2.
For WES, the qualified genomic DNAs from 46 tu-
mors from stage I, 44 tumors from stage III and
matched normal tissues were randomly fragmented,
amplified by ligation-mediated PCR (LM-PCR), purified
and hybridized to the NimbleGen SeqCap EZ exome (44
M, Roche Company, Indianapolis, IN, USA) array for en-
richment. Each captured library was subjected to an
Illumina HiSeq 2000 platform for high-throughput se-
quencing. The mean coverage achieved was 130× in the
tumor and 133× in the normal tissues. A detailed descrip-
tion is presented in Additional file 3: Table S2B. The Agi-
lent SureSelect in Solution is described elsewhere [44].
Illumina sequencing analysis pipeline
For detection of somatic point mutations, sequencing
reads from an Illumina HiSeq 2000 sequencer were
aligned to the human reference genome (hg19) sequence
using Burrows-Wheeler Aligner (BWA) [45]. After re-
moving duplicated reads (redundant information pro-
duced by PCR) using the SAMtools, an in-house cancer
sequencing analysis pipeline (CSAP) was used to identify
somatic mutations [15, 46]. Several recently published
studies have compared the somatic mutation calling
tools (e.g. SomaticSniper, Virmid, Strelka, MuTect and
VarScan2) and found that VarScan2 outperformed all
other tools in detecting high-quality somatic mutations
(high coverage and allele frequency) [47–49]. Therefore,
we detected mutations by VarScan2.2.5 with previously
determined parameters [50]. High-confident SNVs were
annotated with ANNOVAR and used in follow-up ana-
lyses [51]. Briefly, we used an in-house pipeline for stat-
istic sequencing error rates, base calling accuracy and
ATCG base contents of raw sequencing data. Sequence
data per lane needed to meet the following quality con-
trols: i.sequencing error rates ≤ 2.5 %; ii. base calling ac-
curacy, measured by the Phred quality score (Q score),
Q20 ≥ 80 %, Q30 ≥ 75 %; iii. GC or AT separation rate ≤
0.4 %. We applied SOAPnuke to remove adapter and fil-
ter low quality reads [52]. Reads were kept if they met
the following criteria: i. adaptor rate ≤ 10 %; ii. N rate of
every single read ≤ 10 %; iii. low quality base rate (base
quality < 5) of every single read ≤ 50 %. After removing
reads containing sequencing adaptors and low-quality
reads, the high-quality single-end reads were aligned to
the NCBI human reference genome (hg19) using BWA
by default parameters. Each sample should meet the fol-
lowing criteria: i. average sequencing depth of WGS ≥
30×, average sequencing depth of WES ≥ 100×; ii. Map-
ping rate ≥ 95 %; iii. Mismatch rate ≤ 10 %. High-
confident somatic SNVs were called when they met the
following criteria: i. both the tumor and normal samples
should be covered sufficiently (≥10×) at the genomic
position; ii. the variants should be supported by at least
10 % of the total reads in the tumor compared with less
than 2 % in normal tissues; iii. the variants should be
supported by at least three reads in the tumor; iv. dis-
tance between adjacent somatic SNV distance should be
over 10 bp; v. mapping qualities of reads supporting mu-
tant alleles in the tumor should be significantly higher
than 30 (Wilcoxon rank sum test, p < 0.2); vi.base qual-
ities of reads supporting mutant alleles in the tumor
should be significantly higher than 20 (Wilcoxon rank
sum test, p < 0.05); vii.mutations should not be enriched
within 5 bp 5′ or 3′ of read end (Wilcoxon rank sum
test, p < 0.1); viii. the changes of mutant allele frequency
between tumor and normal should be statistically signifi-
cant (Fisher’s exact test, p < 0.05); ix. reads supporting
mutations should not be significantly enriched within ei-
ther forward or reverse genomic strand (Fisher’s exact
test, p < 0.0001).
Detection of small indels
The indel calling step was performed by a GATK Soma-
ticIndelDetector with default parameters [53]. The high-
confident indels were identified by an in-house pipeline
and further annotated with ANNOVAR [51] as either
germline or somatic based on whether any evidence for
the event at the same locus was observed in the normal
data. High-confident somatic insertions and deletions
(indels) were called through the following steps: i. candi-
date somatic indels were predicted with the GATK
SomaticIndel Detector with default parameters; ii.for
each predicted somatic indel, local realignment was per-
formed with combined normal and tumor BAM files; iii.
high-confident somatic indels were defined after filtering
germline events.
Target capture sequencing
To provide high-confident mutations, non-synonymous
mutations identified in the WGS and WES sets were se-
lected for TCS. Briefly, non-synonymous SNVs (6873)
and indels (125) in coding regions identified from 96 of
the 104 samples were designed on a Nimblegen custom-
ized capture array (Roche Company, Indianapolis, IN,
USA). Genomic DNAs from 48 stage I tumors, 48 stage
III tumors and matched normal tissues were fragmented
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and libraries were constructed following the same
method as the exome-capture experiment. For SNVs
and small indels, we tiled ~200 bp targets across the
variant of interest, including a minimum buffer of 100
bp in each direction. After library preparation and
hybridization, sequencing was performed on an Illumina
HiSeq 2000 platform. Each tumor was sequenced to at
least a depth of 300× and SNVs were called with the
same pipeline except that variant allele frequency was
decreased to 5 % to guarantee that low-frequency mu-
tations were retained. Somatic indels were manually
inspected across 104 normal samples to remove
germline mutations. The mean coverage achieved was
365× in TCS with 354× in tumors and 375× in the
normal samples. A detailed description is presented
in Additional file 3: Table S2C. Validation lanes were
aligned to the reference sequence and BAM files cre-
ated in the same manner as described above.
DNA copy number analysis
We performed SegSeq [54], a widely used method to
identify copy number variation (CNVs) by comparing a
tumor sample with a matched normal sample, to infer
somatic CNVs in ESCC genomes based on WGS reads.
The resulting copy number segments were mapped to
individual genes to determine gene-level copy numbers
and copy gain/loss statuses. Copy numbers of ≤ 1.5 were
considered to indicate deletions and ≥ 2.5 were consid-
ered to be amplifications. To infer recurrently amplified
or deleted genomic regions, we re-implemented the GIS-
TIC [21] algorithm using copy numbers in 1 kb windows
as markers instead of SNP array probes. G-scores were
calculated for genomic and gene-coding regions based
on the frequency and amplitude of amplification or dele-
tion of each gene. A significant CNV region was defined
as having an amplification or deletion with G-score >
0.1, corresponding to a p-value threshold of 0.05 from
permutation-derived null distribution.
Identification of significantly mutated genes
For the identification of significantly mutated genes, we
applied a novel analytical methodology, mutation signifi-
cance with covariates (MutSigCV) [10], to avoid the
false-positive findings detected by the standard signifi-
cance analysis method (MutSig1.0) [55]. MutSigCV cor-
rects for variation by using patient-specific mutation
frequency and spectrum and gene-specific background
mutation rates, incorporating expression levels and rep-
lication time. MutSigCV is freely available for non-
commercial use [56].
Pathway enrichment analysis
We performed the pathway enrichment analysis using the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 by examining the distribution of
the non-synonymously mutated genes identified within
the KEGG database [57] as described previously [18]. Sig-
nificantly altered pathways were determined by p-values
calculated based on hypergeometric distribution with Ben-
jamini correction.
Cell lines
KYSE150 and TE1 ESCC cell lines that were tested and
found to be free of mycoplasma contamination were
used in this study. 293 T cells were used as a packaging
cell line to produce virus. All cells were grown in
DMEM/F12 media at 37 °C in 5 % CO2. For the func-
tional analysis of FAM84B, the ESCC lines KYSE150 and
TE-1 with high endogenous expression levels were used
for knockdown experiments.
Knockdown of FAM84B
Knockdown experiments were performed in at least two
ESCC lines with high endogenous FAM84B expression.
Two independent shRNAs were cloned into the pLKO.1-
puro vector (Addgene, Cambridge, MA, USA) as de-
scribed previously [58]. A non-specific targeting shRNA
was also cloned into the pLKO.1-puro vector to be used
as a scrambled control (SCR). shRNA knockdown effi-
ciency was determined by western blot analysis for
FAM84B proteins using an anti-FAM84B antibody (Pro-
teintech, Chicago, USA). Relative expression was normal-
ized to the β-actin expression level.
qPCR copy number validated analysis
The copy numbers of the genes of interest were assessed
in frozen atypical hyperplasia samples using genomic
qPCR (TaqMan, Applied Biosystems, Foster, CA, USA)
in triplicate. Prevalidated primers for the relevant genes
were obtained from Applied Biosystems (accession num-
bers Hs02758348_Cn for MYC, Hs00655850_Cn for
FAM84B, Hs01654625_Cn for VEGFC, Hs05965356_Cn
for FBXW7 and Hs00703603_Cn for FAT1). RNase P
(RPPH1 gene; Life Technologies, Shanghai, China,
4403328) was used as a diploid control. Data were ana-
lyzed using the comparative (delta-Ct) Ct method. An
inferred copy number of < 0.3 was considered to indi-
cate a homozygous deletion.
Fluorescence in situ hybridization analysis
To evaluate the amplification of FAM84B, we performed
FISH. Tumor and matched normal tissues of interesting
ESCC cases were cut into pieces in PBS, swollen in 65
mmol/L KCl for 5 mins at 37 °C, followed by fixation in
cold acetic acid/methanol for 5 mins at 4 °C, then
dropped onto slides. For interphase FISH analysis, slides
were stained with Cytocell enumeration probes against
chromosome 2 or FAM84B conjugated with FITC or
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Cy3.5 (Rainbow Scientific, Windsor, CT, YSA). Probes
against chromosome 2 were used as controls. Staining
was carried out according to the manufacturer’s proto-
col. FISH samples were viewed with a fully automated,
upright Zeiss Axio-ImagerZ.1 microscope with a × 20
objective and DAPI, FITC and Rhodamine filter cubes.
Images were produced using the AxioCamMRm CCD
camera and Axiovision version 4.5 software suite. p-
values were calculated using a two-sample test for equal-
ity of proportions with continuity correction.
Immunohistochemistry and tissue microarray resource
FAM84B was immunohistochemically stained with an
anti-FAM84B antibody (Proteintech, Chicago, USA) as
described previously [18]. A human ESCC tissue array
(OD-CT-DgEso01-001) purchased from Shanghai Outdo
Biotech (Shanghai, China) was used to detect the
expression level of FAM84B. OD-CT-DgEso01-001 array
contains 10 normal esophagus tissues, 22 atypical
hyperplasia tissues and 58 ESCC cases (2cores/case;
Additional file 16: Table S9). FAM84B immunohistochem-
istries were performed on tissue microarraysas previously
described [59], using the polyclonal anti-FAM84B anti-
body (Additional file 17: Figure S8). Briefly, sections were
incubated with the specific antibody at a 1:500 dilution for
14 h at 4 °C, followed by detection using the PV8000
(Zhongshan, Beijing, China) and DAB detection kit
(Maixin, Fuzhou, China), producing a dark brown precipi-
tate. Slides were counterstained with hematoxylin. All im-
ages were captured at × 100. Cytoplasm expression of
FAM84B was quantified using AperioCytoplasma 2.0 soft-
ware. Statistic analyses were performed using Graphpad
Prism 5.0.
Immunoblotting
Immunoblotting was performed as previously described
[19] using anti-FAM84B (Proteintech, Chicago, USA).
Antibody binding was detected using horseradish
peroxidase-labeled anti-mouse (Sigma, Santa clara,USA)
or anti-rabbit (Cell Signaling, Boston,USA) antibodies
and chemiluminescence was measured using a LAS4000
device chemiluminescence System (Sagecreation, Beijing,
China). Equal protein loading was confirmed with anti-
bodies against β-actin (Transgen, Beijing, China).
MTT and migration/invasion assays
To assess cell viability, MTT assays were performed as
previously described [59]. Each experiment consisted of
four replications and at least three independent experi-
ments were carried out. Migration and invasion assays
were performed in 16-well CIM plates in an xCELLi-
gence RTCA DP system (ACEA Biosciences, San Diego,
USA) using BD matrigel basement membrane matrix for
real-time cell migration analysis as described previously
[60, 61]. At least three independent experiments were
carried out; for each independent experiment, five dupli-
cates were performed for each group.
Statistical analysis
Experiments were done in triplicate and data were pre-
sented as mean ± SD. Student’s t-test was used for statis-
tical analysis, and data from more than two groups were
analyzed by one-way analysis of variance (ANOVA) in
SPSS Statistics 19.0 followed by LSD-t test. Results were
considered significant when p < 0.05.
Availability of supporting data
The data sets supporting the results of this article are
available in the European Genome-Phenome Archive re-
pository at Study accession EGAS00001001487 and
Dataset accession EGAD0000100169. Tissue Microarray
data and further details on data access are available from
the GigaScience, GigaDB database [62].
Additional files
Additional file 1: Table S1. Clinical features of the ESCC patients
providing samples for sequencing. (XLSX 22 kb)
Additional file 2: Figure S1. The sequencing data processing pipeline
and calculation of coverage. (a) Sequencing and analytical pipeline for
determining somatic mutations in our cohort. (b) Fold coverage of whole
genome and exome in the sequenced normal and tumor samples in
ESCC. The upper panel: whole-genome sequencing set; the lower panel:
whole-exome sequencing set; lfet: the box plot depicts the distribution
of mean coverage; right: the box plot depicts the distribution of fraction
of bases covered by at least 1 reads, 4 reads, 10 reads and 20 reads across
the sequencing samples. N, normal samples; T, tumor samples; All samples
were calculated with an average estimated tumor content of 40-50 %.
(TIFF 4975 kb)
Additional file 3: Table S2. Sequencing and mapping statistics of the
104 samples. (a) Coverage, mutation, and rearrangement frequencies for
individual samples generated by WGS. (b) Coverage and mutation data
for individual samples generated by WES. (c) Validation of somatic
mutations via target-captured sequencing. (XLSX 26 kb)
Additional file 4: Table S3. Samples and their individual somatic
mutations of exonic and splice-site. (XLSX 14 kb)
Additional file 5: Figure S2. Overview of mutations in ESCC and
comparison with other tumor types. (a) Distribution of non-synonymous
mutations identified in WES set. The red and blue spots represent mutations
of stage I and stage III tumors, respectively. (b) The left pie chart shows the
distribution of mutant regions of the genome as detected by WGS. The
right pie chart indicates the distribution of mutant types in coding region
detected by WGS and WES. (c) The median number of non-synonymous
mutations per tumor in a variety of tumor types. The red text and red arrow
indicates average number of non-synonymous mutations per tumor in our
cohort. (TIFF 8108 kb)
Additional file 6: Figure S3. Comparison of somatic mutations rates
between stage I and stage III tumors. (a) Nonsynonymous somatic
coding mutation rates do not correlate with stage progression. Box plots
showing number of somatic mutations, number of protein-altering
somatic mutations and number of somatic mutations in candidate driver
genes in stage I and stage III patients. Mean ± S.D. are indicated on the
plots. All reported p-values test. (b) Comparison of broad structural genome
alterations between subtypes of stage III tumors. Analysis is based on absolute
copy numbers. Whole-genome sequencing-based analyses reveal that CNVs
of subtypes of stage III show no significant difference. (c) Significant,
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focally amplified (red, upper panel) and deleted (blue, bottom panel)
regions are plotted along the genome. The line represents G-score with
0.1. (TIFF 11404 kb)
Additional file 7: Figure S4. Circos plot of intra- and inter-chromosomal
translocations in all 14 WGS set. (TIFF 5431 kb)
Additional file 8: Table S4. Full list of mutation events identified in our
cohort. (XLSX 11 kb)
Additional file 9: Figure S5. Focally amplified (red) region containing
FAM84B viewed by IGV in 104 cohort is plotted along the chromosome.
(TIFF 11424 kb)
Additional file 10: Figure S6. A two-dimensional map of genetic
alterations in ESCC. The horizontal axis represents genome position from
0 to 250 Mb, and the vertical axis represents genomic alterations including
significantly mutated genes and other genes with mutation frequency
> 2 % along with each chromosome. Significantly mutated genes as
determined by MutSigCV are labeled. Each gene is scaled by a relative
position (0–1) on its chromosome; thus, its position on different
chromosomes was normalized by its total length. The heights of each cone
represent frequencies of mutated genes among 104 patients. (TIFF 4925 kb)
Additional file 11: Table S5. Focal CNAs in WGS set. GISTIC analysis
was performed with 1 M window instead of array probe to identify
significantly copy number alteration. (XLSX 1241 kb)
Additional file 12: Table S6. Summary of significantly mutated genes
and their distributions in stage I and stage III tumors. (a) Significantly
mutated genes identified by MutSigCV analytical method (FDR <0.2).
(b) Summary of frequently mutated genes and their distributions in stage
I and stage III tumors. (XLSX 1846 kb)
Additional file 13: Table S7. NOTCH1 mutations identified in 36 of
atypical hyperplasia tissues through targeted PCR-Sanger sequencing.
(XLSX 266 kb)
Additional file 14: Table S8. Statistically significant pathway with
different frequency in stage I and stage III tumors (P < 0.05). (XLS 27 kb)
Additional file 15: Figure S7. Comparison of SMGs identified in EAC
and ESCC. The star means SMG in the specific cohort. (TIFF 3743 kb)
Additional file 16: Table S9. Summary of clinical data of large-scale
TMA (OD-CT-DgEso01-001, Shanghai Outdo Biotech). (XLSX 200 kb)
Additional file 17: Figure S8. Large-scale TMA analyses depict FAM84B
expression pattern in ESCC tissues. Detail information of cases was shown
in Table S9. (XLS 686 kb)
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